Efficacy and safety of surufatinib and anti-PD-L1 therapy in combination with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma

Table 3 Summary of adverse events by severity, n (%)

Adverse event	Any grade	Grade 1-2	Grade 3	Grade 4	Treatment-related grade ≥ 3
Total	40 (100.0)	28 (70.0)	11 (27.5)	1 (2.5)	12 (30.0)
Hypoalbuminemia	39 (97.5)	39 (97.5)	0	0	0
Abdominal pain	24 (60.0)	22 (55.0)	2 (5.0)	0	2 (5.0)
ALT level elevated	19 (47.5)	19 (47.5)	0	0	0
CRE level elevated	19 (47.5)	19 (47.5)	0	0	0
Anemia	15 (37.5)	14 (35.0)	1 (2.5)	0	1 (2.5)
Hyperbilirubinemia	15 (37.5)	13 (32.5)	2 (5.0)	0	2 (5.0)
Neutropenia	14 (35.0)	13 (32.5)	1 (2.5)	0	1 (2.5)
Thrombocytopenia	14 (35.0)	13 (32.5)	1 (2.5)	0	1 (2.5)
Leukocytopenia	13 (32.5)	12 (30.0)	1 (2.5)	0	1 (2.5)
Vomiting	9 (22.5)	9 (22.5)	0	0	0
Dysuria	6 (15.0)	6 (15.0)	0	0	0
Hypertension	5 (12.5)	1 (2.5)	4 (10.0)	0	4 (10.0)
Nausea	3 (7.5)	3 (7.5)	0	0	0
Chest distress	3 (7.5)	3 (7.5)	0	0	0
Diarrhea	3 (7.5)	3 (7.5)	0	0	0
Allergy	3 (7.5)	2 (5.0)	1 (2.5)	0	1 (2.5)
Ascites	2 (5.0)	2 (5.0)	0	0	0
Constipation	2 (5.0)	2 (5.0)	0	0	0
Insomnia	2 (5.0)	2 (5.0)	0	0	0
Rash	2 (5.0)	2 (5.0)	0	0	0
Poor appetite	1 (2.5)	1 (2.5)	0	0	0
Bloating	1 (2.5)	1 (2.5)	0	0	0
Fever	1 (2.5)	1 (2.5)	0	0	0
HE	1 (2.5)	0	0	1 (2.5)	1 (2.5)

ALT: Alanine transaminase; CRE: Creatinine; HE: Hepatic encephalopathy.